Slomovitz on Tisotumab Vedotin's Promise for Cervical Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Slomovitz on Tisotumab Vedotin's Promise for Cervical Cancer | Targ…
May 1, 2024
targetedonc.com
FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer | OncLive
FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervic…
Nov 1, 2021
onclive.com
Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
Disitamab Vedotin: Promising HER2-Targeted Therapy for Uroth…
Sep 15, 2024
urotoday.com
Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma
Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Ly…
Oct 26, 2017
onclive.com
Improved OS With 1L Brentuximab Vedotin Chemo in Stage III/IV Classical Hodgkin Lymphoma: 6-Year Analysis of ECHELON-1
Improved OS With 1L Brentuximab Vedotin Chemo in Stage III/IV Clas…
392 viewsJul 26, 2022
vumedi.com
3.7K views · 91 reactions | A combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine has been shown to improve progression-free survival in Hodgkin's lymphoma. Data on overall survival are needed. New research findings are summarized in a short video. https://nej.md/3BciZAQ | The New England Journal of Medicine | Facebook
2:15
3.7K views · 91 reactions | A combination of brentuximab vedot…
3.7K views1 week ago
FacebookThe New England Journal of Medicine
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study | OncLive
10:52
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorabl…
Dec 22, 2023
onclive.com
Dr Petrylak on Treatment With Enfortumab Vedotin/Pembrolizum…
Apr 4, 2024
onclive.com
Dr. Monk on the Utility of Tisotumab Vedotin in Recurrent Cervical Can…
Jul 1, 2020
onclive.com
Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent o…
Sep 20, 2021
onclive.com
14:04
EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enf…
Oct 31, 2023
onclive.com
8:43
Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurren…
2 weeks ago
onclive.com
Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL
Nov 10, 2017
onclive.com
Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin Wit…
Mar 20, 2018
onclive.com
ASCO® 2024 Insights: "Impact of Exposure on Outcomes With Enfo…
198 viewsJun 6, 2024
vumedi.com
13:30
innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Ope…
Oct 31, 2023
onclive.com
Dr. Grivas on Enfortumab Vedotin Plus Pembrolizumab in Metastatic …
Feb 6, 2023
onclive.com
Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrol…
May 6, 2024
onclive.com
Erdafitinib versus enfortumab vedotin in previously treated uroth…
Apr 6, 2021
urologytimes.com
2:13
5.5K views · 46 reactions | For patients with recurrent cervical ca…
957 views2 weeks ago
FacebookThe New England Journal of Medicine
Enfortumab Vedotin in the Previously Treated Advanced Hea…
259 viewsJun 29, 2023
vumedi.com
2:51
Adcetris (Brentuximab Vedotin) – What You Need to Know: Uses, Do…
197 viewsAug 24, 2024
YouTubeAstroByte
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid C…
Oct 12, 2021
nejm.org
Dr. Zelenetz Discusses Brentuximab Vedotin | OncLive
1 week ago
onclive.com
3:38
Brentuximab Vedotin Overview and Treatment Advice
2.8K viewsJan 28, 2019
YouTubeOncLive
1:18
The role of enfortumab vedotin in urothelial cancer treatment
360 viewsMay 31, 2024
YouTubeVJOncology
6:36
Enfortumab Vedotin (Padcev) for bladder cancer
378 viewsAug 14, 2024
YouTubePharmComm
POLIVY® (polatuzumab vedotin-piiq) Mechanism of Action
Aug 14, 2023
polivy-hcp.com
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offer…
Aug 8, 2022
ascopost.com
0:55
Dr. Monk on the Mechanism of Action of Tisotumab Vedotin in Re…
420 viewsJun 3, 2020
YouTubeOncLive
See more videos
Static thumbnail place holder